onabotulinumtoxinA, Botox, Botox Cosmetic

1. Antiaging Tips & Secrets Slideshow Pictures
2. Cosmetic Surgery Slideshow Pictures
3. Take the Skin Quiz

Pharmacy Author:

Omudhome Ogbru, PharmD

Omudhome Ogbru, PharmD

Dr. Ogbru received his Doctorate in Pharmacy from the University of the Pacific School of Pharmacy in 1995. He completed a Pharmacy Practice Residency at the University of Arizona/University Medical Center in 1996. He was a Professor of Pharmacy Practice and a Regional Clerkship Coordinator for the University of the Pacific School of Pharmacy from 1996-99.

View Full Profile

Medical and Pharmacy Editor:

Jay W. Marks, MD

Jay W. Marks, MD

Jay W. Marks, MD, is a board-certified internist and gastroenterologist. He graduated from Yale University School of Medicine and trained in internal medicine and gastroenterology at UCLA/Cedars-Sinai Medical Center in Los Angeles.

View Full Profile

GENERIC NAME: onabotulinumtoxinA

BRAND NAME: Botox, Botox Cosmetic

DRUG CLASS AND MECHANISM: OnabotulinumtoxinA is an injectable neuro-toxin, that is, a toxic chemical that blocks the ability of nerves to make muscles contract. In other words, it paralyzes muscles.

To cause muscles to contract, nerves release a chemical, acetylcholine, where they meet muscle cells. The acetylcholine attaches to receptors on the muscle cells and causes the muscle cells to contract or shorten. OnabotulinumtoxinA prevents the release of acetylcholine and thereby prevents contraction of the muscle cells. In order to affect the release of acetylcholine, onabotulinumtoxinA must be injected into the muscle. OnabotulinumtoxinA was approved by the FDA in December 1991.

PRESCRIPTION: Yes

GENERIC AVAILABLE: No

PREPARATIONS: Powder for Injection: 50, 100 or 200 units

STORAGE: Unopened vials or reconstituted onabotulinumtoxinA should be refrigerated at 35.6 to 46.4 F (2 to 8 C). Reconstituted toxin should be used within 24 hours.

PRESCRIBED FOR: OnabotulinumtoxinA is used for the treatment of chronic migraine, axillary hyperhidrosis (excessive sweating in the armpits), and spasticity of the upper arms.

It also is used for cervical dystonia (spasm of the muscles of the neck) to reduce the abnormal head position and neck pain caused by the muscular spasm.

It is injected into the muscles that control the eyeball for treating strabismus (misaligned or lazy eyes) and the muscles of the eyelid for treating blepharospasm (uncontrollable blinking) associated with a condition called dystonia.

It also is effective for managing urinary incontinence associated with neurologic conditions such as multiple sclerosis for which it is injected into the muscular bladder wall to prevent involuntary muscular spasm that leads to incontinence (uncontrollable urination). B

Botox cosmetic is used for reducing glabellar lines (frown lines) in adults 65 years of age or younger.

DOSING: OnabotulinumtoxinA is giving by intramuscular injection. Dosing should be individualized (based on its purpose and the patient in whom it is being used), and the lowest effective dose should be used. OnabotulinumtoxinA is not interchangeable with other preparations of botulinum toxin.

• Chronic Migraine: 155 units divided amongst 31 sites and injected every 12 weeks
• Upper limb spasticity: 75-360 units divided among selected sites. No more than 50 units injected per site; may repeat when effect diminishes but no sooner than every 12 weeks.
• Cervical dystonia: 189-300 units divided among affected muscles. No more than 50 units injected per site.
• Axillary hyperhidrosis: 50 units per arm pit; repeat when effect diminishes.
• Blepharospasm: Initial dose is 1.25-2.5 units. Increase if response is not adequate. There appears to be no benefit in injecting more than 5 units.
• Strabismus: Initial dose is 1.25 to 5 units per muscle; may increase subsequent doses by up to two-fold; maximum dose for each muscle is 25 units.
• Urinary incontinence: 200 units per treatment.

DRUG INTERACTIONS: Administration of onabotulinumtoxinA with other agents (for example, aminoglycosides, curare) that affect neuromuscular function may increase the effect of onabotulinumtoxinA. Use of muscle relaxants may increase the occurrence of weakness. Use of drugs that block acetylcholine may increase some effects of onabotulinumtoxinA.

PREGNANCY: There are no adequate studies of onabotulinumtoxinA in pregnant women.

NURSING MOTHERS: OnabotulinumtoxinA has not been evaluated in nursing mothers

SIDE EFFECTS: Side effects of onabotulinumtoxinA include allergic reactions, rash, itching, headache, neck pain, difficulty swallowing, shortness of breath, nausea, weakness, and dry mouth. Patients also complain of pain and tenderness at the injection site. Patients treated for blepharospasm may experience drooping of the eyelid (ptosis), inflammation of the cornea (keratitis), eye dryness, double vision, tearing, and sensitivity to light. Those treated for urinary incontinence may experience difficulty urinating. Heart attacks, abnormal heart beats, and death have also been reported.

Reference: FDA Prescribing Information

Report Problems to the Food and Drug Administration You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088. Need help identifying pills and medications? Use the pill identifier tool on RxList.